Information Provided By:
Fly News Breaks for September 11, 2017
ICLR
Sep 11, 2017 | 06:46 EDT
BofA/Merrill analyst Ju8an Avendano initiated Icon with a Buy and a $128 price target saying CRO industry fundamentals remain positive and expects the company to leverage its strong biopharma partnerships and advanced data analytics capabilities to grow market share.
News For ICLR From the Last 2 Days
ICLR
Apr 26, 2024 | 08:49 EDT
TD Cowen raised the firm's price target on Icon to $349 from $343 and keeps a Buy rating on the shares. The firm remains positive as they continue to see multiple areas of conservatism built into guide from solid demand environment and expense leverage.
ICLR
ICLR
ICLR
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.